openPR Logo
Press release

GM1 Gangliosidosis Treatment Market

11-14-2023 08:37 AM CET | Health & Medicine

Press release from: DataM Intelligence 4market Research LLP

GM1 Gangliosidosis Treatment Market Size, Share, Industry, Forecast and Outlook (2023-2030)

GM1 Gangliosidosis Treatment Market Size, Share, Industry, Forecast and Outlook (2023-2030)

The GM1 Gangliosidosis Treatment Market is expected to witness substantial growth during the forecast period of 2023-2030. Here's an overview of the dynamics, segment analysis, geographical share, and impact of COVID-19 and the Russia-Ukraine war:

Market Overview:
The global GM1 gangliosidosis treatment market is anticipated to experience significant growth due to factors such as rising lysosomal storage disorders, increased research and development activities, and government investments in pharmaceuticals and biotechnology.

Market Dynamics:
Drivers:
Government Investments and Research: Increasing emphasis on GM1 gangliosidosis treatment through government investments in developing economies is driving the adoption of gene therapy and enhancing the market's growth.
Advancements in Clinical Outcomes: Positive outcomes from clinical trials and advancements in treatment methodologies are contributing to the market's expansion.

Challenges:
Limitations in Therapies: Limitations related to therapies, such as the challenges associated with gene therapy and the limitations of glucosylceramide synthase inhibition, pose challenges in treating GM1 gangliosidosis effectively.

Request for Sample: https://www.datamintelligence.com/download-sample/gm1-gangliosidosis-treatment-market

Segmentation Analysis:
Market Segments: The GM1 gangliosidosis treatment market is segmented based on type, treatment, end-user, and region, with gene therapy showing promising advantages for treatment.

Geographical Share:
North America: Dominates the market, particularly the United States, due to the region's strong presence of major players, increasing healthcare infrastructure investment, and research studies in GM1 gangliosidosis treatment.

COVID-19 Impact:
Supply Chain Disruptions: The COVID-19 pandemic caused significant disruptions in the medical device sector, impacting the demand for GM1 gangliosidosis treatment. Pharmaceutical plants reduced or suspended production due to decreased demand and supply chain disruptions.

Labor Shortages and Safety Measures: Labor shortages and stringent safety measures in pharmaceutical plants led to reduced workforce on-site, impacting crucial activities throughout the pandemic.

Russia-Ukraine War Impact:
The conflict has disrupted clinical trials and therapeutic developments, potentially leading to delays, loss of business continuity, and compliance issues for therapies already in the market. The shift of clinical trials from affected regions to other parts of Europe is being considered.

Key Developments:
Companies like Passage Bio, Lysogene, Sio Gene Therapies, Inc., among others, have released promising safety, biomarker, and clinical development data from their respective clinical trials, showcasing advancements in GM1 gangliosidosis treatment.

Key Companies:
Major players in the GM1 gangliosidosis treatment market include Passage Bio, Lysogene, Sio Gene Therapies, Inc., BioStrategies LC, Sanofi, AZAFAROS, Dorphan S.A., Idorsia Pharmaceuticals Ltd, SphinCS GmbH, and Viatris Inc.

The market for GM1 gangliosidosis treatment continues to evolve with promising advancements in gene therapy and ongoing research and development. However, challenges related to therapeutic limitations and external factors such as the COVID-19 pandemic and geopolitical disruptions pose significant hurdles for the market's growth and stability.

Related Reports:

https://www.datamintelligence.com/download-sample/alpha-mannosidosis-treatment-market
https://www.datamintelligence.com/download-sample/alpha-mannosidosis-treatment-market
https://www.datamintelligence.com/download-sample/mastocytosis-treatment-market

Media Contact
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com/

About DataM Intelligence
DataM Intelligence 4Market Research is a Market Research firm that provides end-to-end business solutions to organizations from Research to Consulting. We at DataM Intelligence leverage our top trademark trends, insights, and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of Syndicate Reports & and; Customized Reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries, catering to the key business research needs that influence the growth trajectory of our vast clientele

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release GM1 Gangliosidosis Treatment Market here

News-ID: 3286490 • Views:

More Releases from DataM Intelligence 4market Research LLP

United States Vegan desserts market to reach $5.8B by 2030 with premium, clean-label, and mainstream adoption growth.
United States Vegan desserts market to reach $5.8B by 2030 with premium, clean-l …
Vegan Dessert Market reached USD 2.9 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 5.8 billion by 2030. The market is growing at a CAGR of 9.1% during the forecast period 2024-2031. The vegan desserts market encompasses a wide range of dairy-free, egg-free, and plant-based sweet products including cakes, cookies, pastries, puddings, chocolates, ice creams, and frozen novelties. These desserts rely on alternatives
United States Tortilla Chips Market Analysis 2025: Consumer Shifts Toward Organic, Baked, and Gluten-Free Products Fueling Growth Opportunities
United States Tortilla Chips Market Analysis 2025: Consumer Shifts Toward Organi …
Tortilla Chips Market reached US$37,900.0 million in 2024 and is expected to reach US$55,447.6 million by 2032, growing at a CAGR of 4.9% from 2025 to 2032. The tortilla chips market refers to the global industry producing and distributing snack foods made primarily from corn, vegetable oils, and seasonings. Tortilla chips are a staple in North American snack culture and have expanded internationally due to their versatility and pairing with dips
United States Baked Savory Snacks Market Forecast to 2031: Trends in Health & Wellness, Clean-Label Demand, Flavor Innovation, and Growth Opportunities
United States Baked Savory Snacks Market Forecast to 2031: Trends in Health & We …
Baked Savory Snacks Market reached USD 48.3 billion in 2022 and is expected to reach USD 77.5 billion by 2030 growing with a CAGR of 6.1% during the forecast period 2024-2031. The Baked Savory Snacks Market refers to the segment of the snack food industry that produces baked products such as crackers, chips, biscuits, breadsticks, pretzels, and other savory items made using baking rather than frying. These snacks are perceived
United States Gluten-Free Biscuits Market Analysis: Rising Consumer Preference for Digestive Health, Sustainable Packaging, and Functional Ingredient Innovation
United States Gluten-Free Biscuits Market Analysis: Rising Consumer Preference f …
Gluten-Free Biscuits Market reached US$ 721.80 million in 2022 and is expected to reach US$ 1278.71 million by 2031, growing with a CAGR of 7.41% during the forecast period 2024-2031. The gluten-free biscuits market refers to the production and distribution of biscuits made without wheat, rye, or barley, which are common sources of gluten. These biscuits are typically formulated with alternative flours such as rice, corn, almond, chickpea, or oats certified

All 5 Releases


More Releases for GM1

GM1 Gangliosidosis Market Expected to Reach USD 1.6 Billion by 2034
GM1 gangliosidosis is a rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme. This results in the accumulation of GM1 gangliosides in cells, primarily affecting the central nervous system. The disease is classified into infantile, juvenile, and adult-onset forms, with infantile GM1 being the most severe and often fatal in early childhood. Download Full PDF Sample Copy of Market Report
GM1 Gangliosidosis Market Massive Growth opportunity Ahead
GM1 Gangliosidosis Market Outlook 2024-2034: Expanding Research, Orphan Drug Approvals, and Regional Growth Introduction GM1 Gangliosidosis is an ultra-rare, inherited lysosomal storage disorder caused by mutations in the GLB1 gene, leading to progressive neurodegeneration. Patients experience a range of symptoms-from developmental delays and skeletal abnormalities to severe motor dysfunction and premature mortality. With no approved curative therapy to date, treatment options remain largely supportive. However, the last decade has witnessed a surge in
GM1 Gangliosidosis Market Size And Global Industry Forecast 2034
Introduction The GM1 Gangliosidosis Market is gaining attention as advancements in genetic research and rare disease drug development open new possibilities for this ultra-rare lysosomal storage disorder. GM1 gangliosidosis is caused by mutations in the GLB1 gene, leading to a deficiency of the β-galactosidase enzyme and progressive neurodegeneration. With no approved curative treatments currently available, ongoing innovation in gene therapy, enzyme replacement therapy (ERT), and small molecule chaperones is fueling significant
GM1 Gangliosidosis Market: Epidemiology, Therapies, Companies, DelveInsight | Pa …
GM1 Gangliosidosis therapies, such as PBGM01, and others, are expected to boost the GM1 Gangliosidosis Market in the upcoming years. DelveInsight has launched a new report on "GM1 Gangliosidosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the GM1 Gangliosidosis, historical and forecasted epidemiology as well as the GM1 Gangliosidosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Discover
GM1 Gangliosidosis Treatment Market Analysis, Status and Business Outlook 2021 t …
Dec 07, 2021 (Market Intelligence Data) --Global GM1 Gangliosidosis Treatment Market Size, Status, and Forecast 2021-2026. In-depth research accumulated to offer Latest insights about acute features of the global GM1 Gangliosidosis Treatment market. This report provides a detailed overview of key factors in the GM1 Gangliosidosis Treatment Market and factors such as driver, restraint, past and current trends, regulatory scenarios and technology development. The impact of the COVID-19 outbreak on the industry was
GM1 Gangliosidosis Treatment Market Higher Mortality Rates by 2027
"Industry analysis is a crucial step in the current competitive market space that helps identify the right target customers and accordingly provide tailored solutions for their business needs. Every aspect and unique challenges put up by the particular industry are carefully taken into consideration while formulating these solutions. It also takes into consideration various government reforms, competitive environment, customer behavior, existing and upcoming business models, and ever-evolving technological developments. Industry